EditorialMyrcludex B, a novel therapy for chronic hepatitis D?
Section snippets
Conflict of interest
The authors who have taken part in this study declared that they do not have anything to disclose regarding funding or conflict of interest with respect to this manuscript.
References (15)
- et al.
Strategies to inhibit entry of HBV and HDV into hepatocytes
Gastroenterology
(2014) - et al.
The entry inhibitor Myrcludex-B efficiently blocks intrahepatic virus spreading in humanized mice previously infected with hepatitis B virus
J Hepatol
(2013) - et al.
Mouse models of hepatitis B and delta virus infection
J Immunol Methods
(2014) - et al.
Optimized HBsAg titer monitoring improves interferon therapy in patients with chronic hepatitis delta
J Hepatol
(2013) - et al.
Treatment of hepatitis D
J Viral Hepat
(2005) - et al.
Pegylated interferon therapy of chronic hepatitis D: in need of revision
Hepatology
(2015) Virology of hepatitis D virus
Semin Liver Dis
(2012)
There are more references available in the full text version of this article.
Cited by (0)
© 2016 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.